101 results about "Streptococcus halichoeri" patented technology

A method to determine the presence or absence of Streptococcus Group A antigen in a sample, comprising the following steps: extracting the antigen from the sample in an assay chamber with two or less extraction reagents, wherein the two reagents may be added to the assay chamber in no particular sequence; introducing a lateral flow immunochromatographic assay device into the extraction reagents containing the extracted antigen without further addition of reagents or manipulation of the sample; forming an antigen-indicator labeling reagent complex; and determining the presence or absence of the antigen in the sample by the presence or absence of a signal formed by the binding of the antigen-indicator labeling reagent complex to an indicator capture reagent specific for said antigen-indicator labeling reagent complex.

The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.

The present invention provides an efficient and inproved process for the production and purification of high molecular weight hyaluronic acid (HA). One embodiment relates to providing growth conditions for production of high molecular weight HA in Streptococcus zooepidemicus. For example, growth in medium comprising a lower protein concentration, e.g., 1% casein hydrolyzate, and a higher sugar concentration, e.g., 5% sucrose, gave 5-6 g / L of high molecular weight HA in the range of 3.5-4.0 x 10Da. The present invention also provides an efficient process for the purification of HA comprising treatment with silica gel then active carbon, and subsequent diafiltration with less volume of solvent.

The present invention provides novel formulations which mitigate agitation-induced aggregation of immunogenic compositions particularly those having polysaccharide-protein conjugates. Specifically, the novel formulations comprise a poloxamer within a molecular weight range of 1100 to 17,400 which provides significant advantages over previously used surfactants including polysorbate 80. In one embodiment, the present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates and a poloxamer. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F or 33F) conjugated to a carrier protein, preferably CRM197.

The invention relates to the field of nucleic acid detection, and particularly relates to an electrochemical sensor for detecting group B streptococcus (GBS) and preparation and an application thereof. The sensor comprises a working electrode, a reference electrode and a counter electrode, wherein the working electrode is obtained by fixing a capturing probe on the surface of a substrate electrode, namely a gold electrode, and the sensor further comprises a template probe, an extension probe and a detection probe which are matched with the capturing probe. The sensor can be used for detecting GBS sensitively, quickly and specifically.

To address the limitations deriving from the unspecific genomic cleavages of the Streptococcus pyogenes Cas9 (SpCas9) and to identify variants with higher cleavage fidelity, the present invention describes a yeast-based assay which allows to simultaneously evaluate the on- and off-target activity towards two engineered genomic targets. The screening of SpCas9 variants obtained by random mutagenesis of the Red-II domain allowed the identification of hits with increased on / off ratios. The best performing nuclease, evoCas9, was isolated through the combination of the identified mutations within asingle variant. Side by side analyses with previously reported rationally designed variants demonstrated a significant improvement in fidelity of evoCas9 of the present invention.

The present invention relates to photon-irradiated streptococcal vaccine preparations and methods for their use.

The invention discloses cefalonium nanosuspension freeze-dried powder and a preparation method of the cefalonium nanosuspension freeze-dried powder. The cefalonium nanosuspension freeze-dried powder is prepared from the following components in parts by weight: 1-5 parts of cefalonium raw drug, 0.1-0.5 part of a surfactant, 0.1-0.5 part of a suspending aid, and 1-10 parts of a freeze-drying protective agent. The cefalonium nanosuspension freeze-dried powder prepared by adopting the preparation method disclosed by the invention has good stability, and is uniform in particle size distribution and good in redispersibility, and the solubility and bioavailability of cefalonium can be improved; an organic solvent is not used in a formula, the use of auxiliary materials is little, the toxic and side effects are small, a preparation process is simple, and the popularization and application are convenient. The cefalonium nanosuspension freeze-dried powder disclosed by the invention has good inhibitory activity for clinical isolates of staphylococcus aureus, streptococcus and escherichia coli.